Newsroom

As part of an ongoing Phase I NIH-funded study, brain tumor patients at NewYork-Presbyterian Hospital/Columbia are being treated with a novel chemotherapy treatment, in which the drug topotecan is administered directly into the brain tumor through catheters. Traditional intravenous chemotherapy cannot treat brain tumors due to limitations caused by the blood-brain barrier, which prevents drugs from entering the brain. NewYork-Presbyterian Hospital and Columbia University Medical Center is the only medical center worldwide where this topotecan treatment is available.

The study hopes to show that the treatment called convection-enhanced delivery is safe and effective, slows tumor growth, improves quality of life, and lengthens survival for patients with malignant and recurrent gliomas the most common type of tumor that originates in the brain.

Seven patients so far have received topotecan, some have experienced side effects, which have been expected and very manageable, says Dr. Jeffrey Bruce, professor of neurological surgery at Columbia University College of Physicians and Surgeons and attending neurosurgeon at NewYork-Presbyterian/Columbia. The drug has previously been shown to reduce tumor size in animal and other laboratory studies.

With convection-enhanced delivery, developed in the mid-1990s by NIH researchers, a slow steady flow of chemotherapy builds up pressure in the brain, pushing the drug into the tumor and surrounding brain tissue. This allows for higher drug concentrations and better distribution of the drug into the brain.

Brain tumors that develop from brain tissue are rare, arising in 15,000 to 20,000 people in the U.S. every year, but they are extremely aggressive. According to Dr. Bruce, radiation and surgery may control the initial mass, but the cancer comes back in nearly 100 percent of cases. Patients typically survive one to three years after diagnosis.

Other NewYork-Presbyterian/Columbia and Columbia University Medical Center physicians involved in the study include Drs. Guy McKhann, Michael Sisti, Casilda Balmaceda, Robert Fine, Joanne Loughlin, Charles Hesdorffer, Peter Canoll, Stephen Sands, Robert DeLaPaz, and Truman Brown.

Topotecan is manufactured by GlaxoSmithKline, of Conshohocken, Pennsylvania, and is sold under the trade name Hycamtin®.

Study participants must have a single, recurrent malignant glioma tumor under 100 cc in size located in the cerebral cortex and have already undergone standard surgical or radiological treatment. For more information, patients may contact Joanne Loughlin at 212-305-1282.

Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, medical education, and health care. The medical center trains future leaders in health care and includes the dedicated work of many physicians, scientists, nurses, dentists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. With a strong history of some of the most important advances and discoveries in health care, its researchers are leading the development of novel therapies and advances to address a wide range of health conditions.

NewYork-Presbyterian Hospital is the largest not-for-profit, non-sectarian hospital in the country. It provides state-of-the-art inpatient, ambulatory, and preventive care in all areas of medicine at five major centers: NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Children's Hospital of NewYork-Presbyterian, the Allen Pavilion, and the Westchester Division. It consistently ranks as one of the top hospitals in the country in U.S. News & World Report's guide to America's Best Hospitals. The NewYork-Presbyterian Healthcare System an affiliation of acute-care and community hospitals, long-term care facilities, ambulatory sites, and specialty institutes serves one in four patients in the New York metropolitan area.